154 related articles for article (PubMed ID: 1364837)
21. An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy.
Kroemer HK; Fromm MF; Bühl K; Terefe H; Blaschke G; Eichelbaum M
Circulation; 1994 May; 89(5):2396-400. PubMed ID: 7910120
[TBL] [Abstract][Full Text] [Related]
22. Influence of the new class I antiarrhythmic agent diprafenone on the end-systolic pressure-volume relationship (conductance technique).
Thormann J; Kramer W; Kremer P; Schlepper M
Cardiovasc Drugs Ther; 1989 Apr; 3(2):145-54. PubMed ID: 2487530
[TBL] [Abstract][Full Text] [Related]
23. Improved synthesis and pharmacologic activity of the enantiomers of a new benzofurane type antiarrhythmic compound.
Ecker G; Fleischhacker W; Helml T; Noe CR; Scasny S; Lemmens-Gruber R; Studenik C; Marei H; Heistracher P
Chirality; 1994; 6(4):329-36. PubMed ID: 8068490
[TBL] [Abstract][Full Text] [Related]
24. The differentiation of propafenone from other class Ic agents, focusing on the effect on ventricular response rate attributable to its beta-blocking action.
Faber TS; Camm AJ
Eur J Clin Pharmacol; 1996; 51(3-4):199-208. PubMed ID: 9010685
[TBL] [Abstract][Full Text] [Related]
25. Enantioselective determination of diprafenone in human plasma.
Zhong D; Chen R; Fieger-Büschges H; Blume H
Pharmazie; 1997 Feb; 52(2):106-9. PubMed ID: 9122271
[TBL] [Abstract][Full Text] [Related]
26. Assessment of the antiarrhythmic profile of the new class I agent diprafenone.
Gülker H; Thale J; Olbing B; Heuer H; Frenking B; Bender F
Arzneimittelforschung; 1985; 35(9):1387-93. PubMed ID: 4084340
[TBL] [Abstract][Full Text] [Related]
27. Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and N-depropylpropafenone.
Malfatto G; Zaza A; Forster M; Sodowick B; Danilo P; Rosen MR
J Pharmacol Exp Ther; 1988 Aug; 246(2):419-26. PubMed ID: 3404440
[TBL] [Abstract][Full Text] [Related]
28. Antiarrhythmic effects of two new propafenone related drugs. A study on four animal models of arrhythmia.
Wascher TC; Dittrich P; Kukovetz WR
Arzneimittelforschung; 1991 Feb; 41(2):119-24. PubMed ID: 2043172
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone.
von Philipsborn G; Gries J; Hofmann HP; Kreiskott H; Kretzschmar R; Müller CD; Raschack M; Teschendorf HJ
Arzneimittelforschung; 1984; 34(11):1489-97. PubMed ID: 6543124
[TBL] [Abstract][Full Text] [Related]
30. Lack of stereoselectivity in the inotropic and phosphodiesterase inhibitory effects of saterinone enantiomers.
Armah BI; Muster D; Raap A; Brückner R; Graziadei I
Arzneimittelforschung; 1989 Nov; 39(11):1384-92. PubMed ID: 2559738
[TBL] [Abstract][Full Text] [Related]
31. The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors.
Nichols AJ; Sulpizio AC; Ashton DJ; Hieble JP; Ruffolo RR
Chirality; 1989; 1(4):265-70. PubMed ID: 2577144
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
[TBL] [Abstract][Full Text] [Related]
33. Drug profile of new benzofurane derivatives in guinea-pig isolated heart muscle preparations.
Lemmens Gruber R; Studenik C; Marei H; Heistracher P
Arch Int Pharmacodyn Ther; 1995; 330(2):165-76. PubMed ID: 8861710
[TBL] [Abstract][Full Text] [Related]
34. Stereoselective electrophysiological effects of propafenone in Langendorff perfused guinea pig hearts.
Stark U; Stark G; Stoschitzky K; Pilger E; Nagl S; Lindner W; Tritthart HA
Basic Res Cardiol; 1992; 87(1):87-97. PubMed ID: 1567355
[TBL] [Abstract][Full Text] [Related]
35. The relative potency of major metabolites and enantiomers of propafenone in an experimental reperfusion arrhythmia model.
Oti-Amoako K; Vozeh S; Ha HR; Follath F
J Cardiovasc Pharmacol; 1990 Jan; 15(1):75-81. PubMed ID: 1688986
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of chronic ventricular arrhythmias with the new class Ic anti-arrhythmia agent diprafenon--results of long-term therapy].
Heuer H; Gülker H; Hasfeld M; Frenking B; Behrenbeck T
Z Kardiol; 1987 Jul; 76(7):415-20. PubMed ID: 3673163
[TBL] [Abstract][Full Text] [Related]
37. Direct separation of the enantiomers of propafenone, diprafenone and their major metabolites by high-performance liquid chromatography on modified cellulose and amylose chiral stationary phases.
Hollenhorst T; Blaschke G
J Chromatogr; 1991 Nov; 585(2):329-32. PubMed ID: 1804845
[No Abstract] [Full Text] [Related]
38. Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors.
Molenaar P; Sarsero D; Arch JR; Kelly J; Henson SM; Kaumann AJ
Br J Pharmacol; 1997 Jan; 120(2):165-76. PubMed ID: 9117106
[TBL] [Abstract][Full Text] [Related]
39. In vitro evidence that carteolol is a nonconventional partial agonist of guinea pig cardiac beta1-adrenoceptors: a comparison with xamoterol.
Floreani M; Froldi G; Quintieri L; Varani K; Borea PA; Dorigo MT; Dorigo P
J Pharmacol Exp Ther; 2005 Dec; 315(3):1386-95. PubMed ID: 16160085
[TBL] [Abstract][Full Text] [Related]
40. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism.
Kroemer HK; Fischer C; Meese CO; Eichelbaum M
Mol Pharmacol; 1991 Jul; 40(1):135-42. PubMed ID: 1857335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
